<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04449185</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0621</org_study_id>
    <nct_id>NCT04449185</nct_id>
  </id_info>
  <brief_title>Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia</brief_title>
  <official_title>Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the investigators' study are to investigate the effect of H.pylori eradication on
      the human gut microbiome and symptoms of functional dyspepsia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accumulating evidence shows that Helicobacter pylori protects against some metabolic and
      immunological diseases in which the development of these diseases coincide with temporal or
      permanent dysbiosis. Helicobacter pylori eradication therapy has the potential to improve
      symptoms of functional dyspepsia. The aims of our study are to investigate the effect of
      H.pylori eradication on the human gut microbiome and symptoms of functional dyspepsia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of gut microbiome</measure>
    <time_frame>at 3 months, and 6 months</time_frame>
    <description>Change of gut microbiome at 3 months, and 6 months regardless of Helicobater positive or negative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom of dyspepsia</measure>
    <time_frame>at 3 months, and 6 months</time_frame>
    <description>Improvement of NDI-K, HADS,SEQ-FD at 3 and 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of helicobacter pylori</measure>
    <time_frame>at 3 months</time_frame>
    <description>Eradication rate of helicobacter pylori at 3 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histologic finding of UGI tract</measure>
    <time_frame>at initial and 3 months</time_frame>
    <description>Change of accumulationof inflammatory cells, eosinophils of esophagus, stomachm duodenal mucosal biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dyspepsia</condition>
  <arm_group>
    <arm_group_label>HP eradication group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HP eradication group
Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days</intervention_name>
    <description>Tegoprazan 50mg bid + amoxicillin 1000mg bid + clarithromycin 500mg bid for 10 days</description>
    <arm_group_label>HP eradication group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who has diagnosed with functional dyspesia by Rome IV criteria

        Exclusion Criteria:

          -  Known GI malignancy

          -  Previous Helicobater pylori eradication history

          -  Severe systemic disease

          -  Previous GI surgery

          -  Uncorrectable coagulopathy: INR &gt; 1.5 or platelet &lt; 50,000/ml

          -  Pregnant or breastfeeding women

          -  Atrophic gastritis, open type
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kee Wook Jung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kee Wook Jung, MD, PhD</last_name>
    <phone>821026778856</phone>
    <email>jung.keewook30@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ga Hee Kim, MD, PhD</last_name>
    <phone>821028732884</phone>
    <email>smallgh@hanmail.net</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>June 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2020</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Kee Wook Jung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Dyspepsia</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Eradication therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clarithromycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

